Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)

doi:10.19401/j.cnki.1007-3639.2023.12.004

Abstract

Abstract:

According to the latest data released by the International Agency for Research on Cancer of the World Health Organization (WHO), breast cancer has become the malignant tumor with the highest incidence rate around the world, seriously endangering the physical and mental health of women. Since the Society of Breast Cancer China Anti-Cancer Association firstly formulated “guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2007 edition)” in 2007, a total of 8 editions have been updated. The guidelines have been keeping pace with the times, taking into account the authority of evidence, the cutting-edge knowledge and the practicality in the vast grassroots. The “guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition)” has been updated on the basis of the 2021 Edition, incorporating new concepts of breast cancer diagnosis and classification, new methods for precision treatment, new specifications for surgical procedures and new plans for comprehensive treatment, aiming to provide guidance and basis for medical staff in the field of breast cancer prevention, control, diagnosis and treatment.

Key words: Breast cancer, Diagnosis, Treatment, Guideline

CLC Number:

R737.9

The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)[J]. China Oncology, 2023, 33(12): 1092-1187.

Figures/Tables 29

References 86

[1]	WHO Classification of Tumours Editorial Board. Breast tumours[M]. 5th ed. Lyon: International Agency for Research on Cancer, 2019.
[2]	NCCN Clinical Practice Guideline in Oncology^TM. Breast Cancer. 2014 National Comprehensive Cancer Network[EB/OL]. https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1419[2021-09-02].
[3]	American Joint Committee on Cancer. AJCC cancer staging handbook[M]. 7th ed. Chicago: Springer, 2010.
[4]	BUCHHOLZ T A, SOMERFIELD M R, GRIGGS J J, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage Ⅰ and Ⅱ invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline[J]. J Clin Oncol, 2014, 32(14): 1502-1506. doi: 10.1200/JCO.2014.55.1572
[5]	KUNKLER I H, WILLIAMS L J, JACK W J, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial[J]. Lancet Oncol, 2015, 16(3): 266-273. doi: 10.1016/S1470-2045(14)71221-5
[6]	GIULIANO A E, MCCALL L, BEITSCH P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J]. Ann Surg, 2010, 252(3): 426-432; discussion 432-433. doi: 10.1097/SLA.0b013e3181f08f32 pmid: 20739842
[7]	DONKER M, VAN TIENHOVEN G, STRAVER M E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12): 1303-1310. doi: 10.1016/S1470-2045(14)70460-7 pmid: 25439688
[8]	MORAN M S, SCHNITT S J, GIULIANO A E, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer[J]. J Clin Oncol, 2014, 32(14): 1507-1515. doi: 10.1200/JCO.2013.53.3935
[9]	EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018, 19(1): 27-39. doi: S1470-2045(17)30777-5 pmid: 29242041
[10]	GIANNI L, PIENKOWSKI T, IM Y H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800. doi: S1470-2045(16)00163-7 pmid: 27179402
[11]	SIKOV W M, BERRY D A, PEROU C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[12]	ADAMS S, LOI S, TOPPMEYER D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 405-411. doi: 10.1093/annonc/mdy518
[13]	ADAMS S, SCHMID P, RUGO H S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404. doi: 10.1093/annonc/mdy517
[14]	GOETZ M P, TOI M, CAMPONE M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646. doi: 10.1200/JCO.2017.75.6155 pmid: 28968163
[15]	ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533. doi: 10.1056/NEJMoa1706450
[16]	SLEDGE G W Jr, TOI M, NEVEN P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J]. J Clin Oncol, 2017, 35(25): 2875-2884. doi: 10.1200/JCO.2017.73.7585 pmid: 28580882
[17]	SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. doi: 10.1056/NEJMoa1809615
[18]	TRIPATHY D, IM S A, COLLEONI M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915. doi: S1470-2045(18)30292-4 pmid: 29804902
[19]	TURNER N C, SLAMON D J, RO J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer[J]. N Engl J Med, 2018, 379(20): 1926-1936. doi: 10.1056/NEJMoa1810527
[20]	BLOK E J, KROEP J R, MEERSHOEK-KLEIN KRANENBARG E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1).
[21]	BURSTEIN H J, LACCHETTI C, ANDERSON H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol, 2019, 37(5): 423-438. doi: 10.1200/JCO.18.01160 pmid: 30452337
[22]	FRANCIS P A, PAGANI O, FLEMING G F, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J]. N Engl J Med, 2018, 379(2): 122-137. doi: 10.1056/NEJMoa1803164
[23]	GNANT M, MLINERITSCH B, STOEGER H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12[J]. Ann Oncol, 2015, 26(2): 313-320. doi: 10.1093/annonc/mdu544 pmid: 25403582
[24]	MAMOUNAS E P, BANDOS H, LEMBERSKY B C, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(1): 88-99. doi: S1470-2045(18)30621-1 pmid: 30509771
[25]	METZGER FILHO O, GIOBBIE-HURDER A, MALLON E, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial[J]. J Clin Oncol, 2015, 33(25): 2772-2779. doi: 10.1200/JCO.2015.60.8133 pmid: 26215945
[26]	PAN H C, GRAY R, BRAYBROOKE J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med, 2017, 377(19): 1836-1846. doi: 10.1056/NEJMoa1701830
[27]	BLUM J L, FLYNN P J, YOTHERS G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology)[J]. J Clin Oncol, 2017, 35(23): 2647-2655. doi: 10.1200/JCO.2016.71.4147 pmid: 28398846
[28]	CARDOSO F, VAN'T VEER L J, BOGAERTS J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729. doi: 10.1056/NEJMoa1602253
[29]	EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001): 1353-1361. doi: S0140-6736(15)60908-4 pmid: 26211824
[30]	EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019, 393(10179): 1440-1452. doi: 10.1016/S0140-6736(18)33137-4
[31]	LOIBL S, WEBER K E, TIMMS K M, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto[J]. Ann Oncol, 2018, 29(12): 2341-2347. doi: S0923-7534(19)34246-2 pmid: 30335131
[32]	MASUDA N, LEE S J, OHTANI S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159. doi: 10.1056/NEJMoa1612645
[33]	MOORE H C, UNGER J M, PHILLIPS K A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10): 923-932. doi: 10.1056/NEJMoa1413204
[34]	NITZ U, GLUZ O, CLEMENS M, et al. West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol, 2019, 37(10): 799-808. doi: 10.1200/JCO.18.00028 pmid: 30785826
[35]	SPARANO J A, GRAY R J, MAKOWER D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2): 111-121. doi: 10.1056/NEJMoa1804710
[36]	PROWELL T M, BEAVER J A, PAZDUR R. Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer[J]. N Engl J Med, 2019, 380(7): 612-615. doi: 10.1056/NEJMp1900079
[37]	SPARANO J A, GRAY R J, RAVDIN P M, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25): 2395-2405. doi: 10.1056/NEJMoa1904819
[38]	EARL H M, HILLER L, VALLIER A L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet, 2019, 393(10191): 2599-2612. doi: S0140-6736(19)30650-6 pmid: 31178152
[39]	MARTIN M, HOLMES F A, EJLERTSEN B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1688-1700. doi: S1470-2045(17)30717-9 pmid: 29146401
[40]	VON MINCKWITZ G, HUANG C S, MANO M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628. doi: 10.1056/NEJMoa1814017
[41]	VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131. doi: 10.1056/NEJMoa1703643
[42]	GIANNI L, PIENKOWSKI T, IM Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32. doi: 10.1016/S1470-2045(11)70336-9 pmid: 22153890
[43]	MA F, LI Q, CHEN S S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112. doi: 10.1200/JCO.2016.69.6179 pmid: 28498781
[44]	LANG G T, JIANG Y Z, SHI J X, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing[J]. Nat Commun, 2020, 11(1): 5679. doi: 10.1038/s41467-020-19342-3
[45]	JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5. doi: 10.1016/j.ccell.2019.02.001
[46]	LI J J, YU K D, PANG D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(16): 1774-1784. doi: 10.1200/JCO.19.02474
[47]	YU K D, YE F G, HE M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1390-1396. doi: 10.1001/jamaoncol.2020.2965
[48]	WANG X, WANG S S, HUANG H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial[J]. JAMA, 2021, 325(1): 50-58. doi: 10.1001/jama.2020.23370
[49]	HU X C, ZHANG J, XU B H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 436-446. doi: 10.1016/S1470-2045(15)70064-1
[50]	ZHANG J, LIN Y, SUN X J, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase Ⅲ trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2018, 29(8): 1741-1747. doi: 10.1093/annonc/mdy209
[51]	LIN M X, CHEN Y, JIN Y Z, et al. Comparative overall survival of CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone for hormone receptor-positive, HER2-negative metastatic breast cancer[J]. J Cancer, 2020, 11(24): 7127-7136. doi: 10.7150/jca.48944
[52]	FALLON M, GIUSTI R, AIELLI F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv166-iv191. doi: 10.1093/annonc/mdy152
[53]	ZHAO S, MA D, XIAO Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance[J]. Oncologist, 2020, 25(10): e1481-e1491. doi: 10.1634/theoncologist.2019-0982
[54]	JIANG Y Z, LIU Y, XIAO Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186. doi: 10.1038/s41422-020-0375-9
[55]	ALBABTAIN H, ALWHAIBI M, ALBURAIKAN K, et al. Quality of life and complementary and alternative medicine use among women with breast cancer[J]. Saudi Pharm J, 2018, 26(3): 416-421. doi: 10.1016/j.jsps.2017.12.020 pmid: 29556133
[56]	林洪生, 刘杰, 张英. 《恶性肿瘤中医诊疗指南》的内涵及其意义[J]. 中国肿瘤临床与康复, 2016, 23(3): 257-260.
	LIN H S, LIU J, ZHANG Y. Connotation and significance of “Guidelines for Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine”[J]. Chin J Clin Oncol Rehabil, 2016, 23(3): 257-260.
[57]	陈前军, 裴晓华. 早期乳腺癌中医辨证内治专家共识[J]. 现代中医临床, 2020, 27(3): 5-8.
	CHEN Q J, PEI X H. Consensus on TCM syndrome differentiation and internal therapy for early-stage breast cancer[J]. Mod Chin Clin Med, 2020, 27(3): 5-8.
[58]	杨雯靖, 念家云, 杨国旺. 中西医结合治疗乳腺癌现状及展望[J]. 北京中医药, 2020, 39(10): 1009-1013.
	YANG W J, NIAN J Y, YANG G W. Present situation and prospect of treating breast cancer with integrated traditional Chinese and western medicine[J]. Beijing J Tradit Chin Med, 2020, 39(10): 1009-1013.
[59]	马瑞, 张丹, 林从尧. 小金丸、逍遥丸及乳癖散结胶囊治疗乳腺增生的临床观察[J]. 现代中西医结合杂志, 2015, 24(2): 140-142.
	MA R, ZHANG D, LIN C Y. Clinical observation of Koganemaru, Xiaoyao Pill and Rubisanjie Capsule in the treatment of mammary hyperplasia[J]. Mod J Integr Tradit Chin West Med, 2015, 24(2): 140-142.
[60]	《乳腺癌HER检测指南版》编写组. 《乳腺癌HER2检测指南(2019版)》[J]. 中华病理学杂志, 2019, 48(3): 169-175.
	HER2 Detection Guidline for Breast Cancer (2019 Edition) Writing Group. HER2 guideline for breast cancer (2019 Edition)[J]. Chin J Pathol, 2019, 48(3): 169-175.
[61]	《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组. 乳腺癌新辅助治疗的病理诊断专家共识(2020版)[J]. 中华病理学杂志, 2020, 49(4): 296-304.
	Expert Consensus on Pathological Diagnosis of Neoadjuvant Therapy for Breast Cancer (2020 Edition) Writing Group. Writing Group. Expert consensus on pathological diagnosis of neoadjuvant therapy for breast cancer (2020 Edition)[J]. Chin J Pathol, 2020, 49(4): 296-304.
[62]	《乳腺癌雌、孕激素受体检测指南》编写组. 乳腺癌雌、孕激素受体检测指南[J]. 中华病理学杂志, 2015, 44(4): 237-240.
	Guidelines for Detection of Estrogen and Progesterone Receptors in Breast Cancer Writing Group. Guidelines for detection of estrogen and progesterone receptors in breast cancer[J]. Chin J Pathol, 2015, 44(4): 237-240.
[63]	GOLDHIRSCH A, INGLE J N, GELBER R D, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20(8): 1319-1329. doi: 10.1093/annonc/mdp322 pmid: 19535820
[64]	GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747. doi: 10.1093/annonc/mdr304
[65]	GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. doi: 10.1093/annonc/mdt303 pmid: 23917950
[66]	WRIGHT M J, PARK J, FEY J V, et al. Perpendicular inked versus tangential shaved margins in breast-conserving surgery: does the method matter?[J]. J Am Coll Surg, 2007, 204(4): 541-549. doi: 10.1016/j.jamcollsurg.2007.01.031
[67]	ELSTON C W, ELLIS I O. Pathological prognostic factors in breast cancer.Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up[J]. Histopathology, 2002, 41(3a): 154-161. doi: 10.1046/j.1365-2559.2002.14892.x
[68]	FRIERSON H F Jr, WOLBER R A, BEREAN K W, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma[J]. Am J Clin Pathol, 1995, 103(2): 195-198. doi: 10.1093/ajcp/103.2.195 pmid: 7856562
[69]	HAMMOND M E, HAYES D F, DOWSETT M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. Arch Pathol Lab Med, 2010, 134(6): 907-922. doi: 10.1043/1543-2165-134.6.907 pmid: 20524868
[70]	DOWSETT M, NIELSEN T O, A’HERN R, et al. Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656-1664. doi: 10.1093/jnci/djr393
[71]	WOLFF A C, HAMMOND M E, HICKS D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013. doi: 10.1200/JCO.2013.50.9984 pmid: 24101045
[72]	SYMMANS W F, PEINTINGER F, HATZIS C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007, 25(28): 4414-4422. doi: 10.1200/JCO.2007.10.6823 pmid: 17785706
[73]	OGSTON K N, MILLER I D, PAYNE S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast, 2003, 12(5): 320-327. doi: 10.1016/s0960-9776(03)00106-1 pmid: 14659147
[74]	水若鸿, 杨文涛. 乳腺癌Ki-67阳性指数的检测和评估[J]. 中华病理学杂志, 2013, 42(6): 420-423.
	SHUI R H, YANG W T. Detection and evaluation of Ki-67 positive index in breast cancer[J]. Chin J Pathol, 2013, 42(6): 420-423.
[75]	LIN M X, JIN Y Z, YANG Z Y, et al. Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211022881.
[76]	ZHANG J F, LIN M X, JIN Y Z, et al. Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia[J]. Breast Cancer Res Treat, 2020, 182(3): 719-726. doi: 10.1007/s10549-020-05730-2
[77]	《肿瘤病理诊断规范》项目组. 肿瘤病理诊断规范(乳腺癌)[J]. 中华病理学杂志 2016, 45(8): 525-528.
	The project team of Tumor Pathological Diagnosis Standard. Diagnostic criteria for tumor pathology (breast cancer)[J]. Chin J Pathol, 2016, 45 (8): 525-528.
[78]	《中国乳腺导管原位癌病理诊断共识2022版》编写组. 中国乳腺导管原位癌病理诊断共识(2022版)[J]. 中华病理学杂志, 2022, 51(9): 812-818.
	The Writing Team of the Chinese Consensus on Pathological Diagnosis of Breast Ductal Carcinoma in situ (2022 Edition). Chinese consensus on pathological diagnosis of ductal carcinoma in situ of the breast (2022 edition)[J]. Chin J Pathol, 2022, 51 (9): 812-818.
[79]	杨昭志, 孟晋, 马金利, 等. 早期乳腺癌术后靶区勾画共识[J]. 中国癌症杂志, 2019, 29(9): 753-760.
	YANG Z Z, MENG J, MA J L, et al. Early stage breast cancer postoperative target volume contouring[J]. China Oncol, 2019, 29(9)753-760
[80]	WOLFF A C, ELIZABETH HALE HAMMOND M, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122. doi: 10.1200/JCO.2018.77.8738 pmid: 29846122
[81]	WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872. doi: 10.1200/JCO.22.02864
[82]	TARANTINO P, VIALE G, PRESS M F, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659. doi: 10.1016/j.annonc.2023.05.008 pmid: 37269905
[83]	SHI F, LIANG Z, ZHANG Q, et al. The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis[J]. Breast, 2018, 39: 39-45. doi: S0960-9776(18)30053-5 pmid: 29574393
[84]	HUXLEY N, JONES-HUGHES T, COELHO H, et al. Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer[J]. Health Technol Assess, 2015, 19(2): Ⅴ-ⅩⅩⅤ.
[85]	BUNDRED J R, MICHAEL S, STUART B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis[J]. BMJ, 2022, 378: e070346.
[86]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
	The Society of Breast Cancer China Anti-Cancer Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040.

适应证	禁忌证	豁免前哨淋巴结活检
早期浸润性乳腺癌	炎性乳腺癌	肿瘤完整切除并经石蜡包埋组织病理完全评估为DCIS
性别不限	临床ALN阳性（cN+）并经穿刺活检证实	≥70岁（伴随疾病），cT₁N₀M₀，HR阳性HER2阴性，辅助治疗不受腋窝状态影响^g
临床ALN阴性（cN₀） ^a	cN+新辅助治疗后仍为阳性	cT₁N₀且影像±穿刺活检评估腋淋巴结阴性、接受保乳手术及全乳照射^h
单灶或多中心性病变	cN_2-3新辅助治疗后临床阴性
DCIS全乳切除手术或保乳手术原发肿瘤切除影响随后SLNB成功率和准确性^b
cN0新辅助治疗后临床腋窝阴性
穿刺证实的cN₁新辅助治疗后临床腋窝阴性^c
妊娠患者^d
保乳联合SLNB术后同侧乳房复发/再发^e
腋窝淋巴结临床查体阴性但影像学1 ~ 2枚异常并穿刺活检证实转移（有争议的适应证）^f

危险度^a	判别要点
危险度^a	区域淋巴结转移	其他情况
低危	阴性	同时具备以下条件^b：pT≤2 cm；组织学Ⅰ级； LVI阴性； HER2阴性；年龄>35岁； ER/PR阳性^c； Ki-67增殖指数≤20%或实验室中位值
		ER阳性HER2阴性时, 不满足上述其他条件但多基因检测低危
中危	不符合低/高危定义的其他情况
高危	1 ~ 3枚阳性	ER/PR阳性且HER2阴性时, 满足以下条件之一^d：组织学III级； pT>5 cm；多基因检测高危
		ER阴性且PR阴性；或HER2阳性
	≥4枚阳性	任何情况

内在分子分型	基于IHC4的分子分型	备注
Luminal A型	Luminal A样 ER/PR阳性且PR高表达HER2阴性 Ki-67增殖指数低	ER、PR表达及Ki-67增殖指数的判定值建议采用报告阳性细胞的百分比。 Ki-67增殖指数的判定值在不同病理实验中心可能不同，可采用20%~30%作为判断Ki-67增殖指数高低的界值；同时，以20%作为PR表达高低的判定界值^*，可进一步区分Luminal A样和Luminal B样（HER2阴性）
Luminal B型	Luminal B样（HER2阴性） ER/PR阳性 HER2阴性且Ki-67增殖指数高或PR低表达	上述不满足Luminal A样条件的Luminal样肿瘤均可作为Luminal B样亚型
	Luminal B样（HER2阳性） ER/PR阳性 HER2阳性（蛋白过表达或基因扩增）任何状态的Ki-67增殖指数
ERBB2+型	HER2阳性 HER2阳性（蛋白过表达或基因扩增） ER阴性和PR阴性
Basal-like型	三阴性（非特殊型浸润性导管癌） ER阴性 PR阴性HER2阴性	TNBC和Basal-like型乳腺癌之间的吻合度约80%；但是TNBC也包含一些特殊类型乳腺癌如分泌性癌和腺样囊性癌等

复发风险度	激素受体阳性HER2阴性	HER2阳性	TNBC
低危	豁免化疗	不适用	不适用
中危且pN₀^b	·T₃及以上推荐化疗 ·T_1b-T₂：考虑多基因检测工具，目前指导辅助化疗的主要是21基因或70基因检测 - 21基因：年龄>50岁且RS>25 推荐化疗 - 21基因：年龄≤50岁日RS≥16 推荐化疗 - 70基因：临床高风险^a且70基因高风险推荐化疗 - 70基因：临床高风险^a且年龄≤50岁且70基因低风险考虑化疗 ·T_1b~T₂：未接受基因检测，具有如下特征之一的可考虑化疗：ER低表达组织学3级，LVI阳性，年龄≤35岁，高Ki-67增殖指数^c ·T_1a：原则上豁免化疗，除非同时伴有多个风险因素时个体化综合考虑	·T_1c及以上推荐 ·T_1a-b考虑^d ·T_1mic原则上不考虑，需个体化综合评估，如年龄、LVI、多灶与否等	·T_1c及以上推荐 ·T_1a-b考虑 ·T_1mic原则上不考虑，需个体化综合评估，如年龄、LVI、多灶与否等
中危且pN₁	·均推荐化疗 ·除非T_1-2且接受21基因或70基因检测时，如下结果才考虑豁免化疗： - 21基因： RS≤11的患者^e - 70基因：临床高风险^a，70基因低风险且年龄>50岁的患者	不适用	不适用
高危	均推荐化疗	均推荐化疗	均推荐化疗

风险度分层	初始治疗			后续强化治疗
风险度分层	推荐	考虑	可选	推荐	考虑	可选
中危（pT_1aN₀）	·缺乏高级别证据	·wP+H	·TC+H ·其他个体化方案或临床研究（如口服化疗+H，H+内分泌治疗）	·无	-	-
中危（pT_1bN₀）	·wP+H	·TC+H	·TCbH ·EC-T(wP)+H	·无	-	-
中危（pT_1c及以上，N₀）	·EC-T(wP)+H ·TCB+H	·TC+H	·EC-T(wP)+HP ·TCb+HP	·无	-	·奈拉替尼
高危（任何pN⁺）	·EC-T(wP)+HP ·TCb+HP	-	-	-	·奈拉替尼	·其他TKI